Five Zepbound labeling supplements approved at once
On October 18, 2024, the FDA approved five labeling updates for Zepbound (tirzepatide) at once, including one tied to new clinical trial data, though the source does not detail the specific new claims.
The Food and Drug Administration approved five separate labeling supplements for Zepbound (tirzepatide) on the same day, October 18, 2024, according to FDA's Drugs@FDA database entry for New Drug Application 217806, held by Eli Lilly and Co [1]. The five supplements are listed as SUPPL-5, SUPPL-6, SUPPL-11, SUPPL-15 and SUPPL-19 [1].
Zepbound was originally approved on November 8, 2023, under a priority review [1]. The drug is sold in a range of tirzepatide strengths, from 2.5 mg up to 60 mg per dose, across single-dose vials and pen devices including the Zepbound autoinjector and Zepbound KwikPen [1].
Of the five supplements approved that day, one — SUPPL-6 — is categorized by FDA as an "Efficacy-Labeling Change With Clinical Data," meaning it involved new clinical trial information added to the drug's label [1]. The other four supplements approved the same day were administrative or format changes to the package insert and medication guide: SUPPL-5 and SUPPL-19 both covered labeling for the package insert and medication guide, SUPPL-11 covered the package insert only, and SUPPL-15 covered the package insert and medication guide as well [1]. All five actions share a single combined label document and a single approval letter dated October 18, 2024 [1].
The source record does not spell out what the new clinical data in SUPPL-6 said or which section of the label it changed. It also does not explain why five separate supplements were grouped into one action date, though FDA regularly finalizes multiple pending submissions together when they are related or when their reviews conclude around the same time.
Why it matters for patients
A labeling update tied to clinical data can mean new information about how well the drug works, new side effect data, a changed dosing instruction, or updated guidance for a specific patient group. Because the source here only names the regulatory category and not the substance of the change, patients cannot tell from this record alone what changed in their prescribing information. Anyone using Zepbound who wants specifics would need to compare the actual label text from before and after October 18, 2024, using the linked label PDF for submissions s005, s006, s011, s015 and s019 [1].
Label changes like this are a normal part of a drug's life cycle after approval. They can reflect ongoing trial results, manufacturing updates, or FDA's own review of new safety reports. The fact that four of the five October 2024 supplements were administrative — covering package insert and medication guide formatting — suggests much of this batch was about presentation rather than new medical findings, but the fifth, SUPPL-6, was substantive enough to be labeled an efficacy change with clinical data [1].
What happens next
FDA's record for this NDA shows further label activity after October 2024. On December 20, 2024, the agency approved SUPPL-13, described as an "Efficacy-New Indication," meaning Zepbound's approved uses expanded again [1]. Additional supplements followed through 2025 and into 2026, including package insert and medication guide updates on February 7, 2025, and September 25, 2025, a manufacturing formulation change in January 2026, and another efficacy-labeling change with clinical data, SUPPL-41, dated August 26, 2026 [1]. Each of these represents a separate labeling action whose specific content is not detailed in this database entry.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.